C630004H02Rik Inhibitors
Chemical inhibitors of C630004H02Rik encompass a range of compounds that target various kinases implicated in cell cycle regulation and signal transduction pathways. Alsterpaullone, Roscovitine, Olomoucine, Indirubin-3'-monoxime, and Flavopiridol are specific inhibitors of Cyclin-dependent kinases (CDKs), which play a pivotal role in the control of the cell cycle. By inhibiting CDKs, these compounds can disrupt the cell cycle processes that are essential for the normal function of C630004H02Rik in neuronal cells. Alsterpaullone and Flavopiridol, in particular, exhibit a potent capacity to hinder CDK activity, which directly influences the progression through various phases of the cell cycle, a fundamental aspect for the differentiation and function of neurons. Roscovitine and Olomoucine share a similar mechanism, selectively targeting CDKs to impede their activity and, therefore, the cell cycle-dependent functions of C630004H02Rik.
In parallel, LY294002 and Wortmannin act as inhibitors of phosphoinositide 3-kinases (PI3K), which are critical for a wide array of cellular functions, including survival, growth, and differentiation. The inhibition of PI3K by these compounds can lead to the modulation of downstream signaling pathways that are vital for the functional role of C630004H02Rik in neurons. Additionally, PD98059, U0126, and SL327, which inhibit MEK, along with SP600125 and SB203580, which target JNK and p38 MAPK respectively, affect the MAPK pathway. The MAPK pathway is integral to various cellular processes, including neuronal differentiation, plasticity, and apoptosis. The action of these inhibitors on their respective targets within the MAPK pathway can influence the signaling required for the functional role of C630004H02Rik. By modulating these kinase activities, the compounds can effectively alter the regulatory processes in which C630004H02Rik is involved, particularly those related to neuronal cell function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits Cyclin-dependent kinases (CDKs) which are integral for cell cycle progression. As C630004H02Rik is involved in neuronal differentiation and function, which can be cell cycle-dependent, inhibition of CDKs by Alsterpaullone likely leads to functional inhibition of C630004H02Rik by disrupting neuronal cell cycle processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, which are necessary for cell cycle control and neuronal function. Inhibition of these kinases by Roscovitine would likely impair the cell cycle-related functions of C630004H02Rik in neurons. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor with a mechanism similar to Roscovitine. By inhibiting CDKs, Olomoucine would functionally inhibit processes that are necessary for C630004H02Rik's role in neuronal function and differentiation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a potent inhibitor of CDKs. Its action on these kinases would inhibit cell cycle progression and neuronal differentiation, processes in which C630004H02Rik is functionally involved. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol strongly inhibits CDKs, and by doing so, it likely impedes the cell cycle and differentiation pathways that are essential for the functional role of C630004H02Rik in neuronal cells. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, a kinase involved in a myriad of signaling pathways including neuronal survival and function. Inhibition of PI3K by LY294002 can functionally inhibit signaling pathways that are essential for the role of C630004H02Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that would disrupt the PI3K/AKT pathway. Given that C630004H02Rik is involved in neuronal function, inhibition of PI3K by Wortmannin would likely lead to functional inhibition of C630004H02Rik by disrupting downstream neuronal signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK pathway. This pathway is implicated in neuronal differentiation and plasticity, and its inhibition by PD98059 could lead to functional inhibition of C630004H02Rik by impairing necessary signaling for its role in neurons. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also targets MEK in the MAPK pathway, similar to PD98059, and would therefore be expected to functionally inhibit C630004H02Rik by blocking the signaling required for its role in neuronal differentiation and function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. JNK signaling is involved in neuronal function and apoptosis. Inhibition of JNK by SP600125 could functionally inhibit C630004H02Rik by disrupting signaling pathways crucial to its neuronal role. | ||||||